HIV/AIDS MEASURES GROUP OVERVIEW

2012 PHYSICIAN QUALITY REPORTING OPTIONS FOR MEASURES GROUPS: REGISTRY ONLY

2012 PHYSICIAN QUALITY REPORTING MEASURES IN HIV/AIDS MEASURES GROUP:
#159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage
#160. HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
#161. HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy
#162. HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy
#205. HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea
#206. HIV/AIDS: Screening for High Risk Sexual Behaviors
#207. HIV/AIDS: Screening for Injection Drug Use
#208. HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis

INSTRUCTIONS FOR REPORTING: (These instructions apply to registry reporting. Do not report this measures group via claims.)

- It is not necessary to submit the measures group-specific intent G-code for registry-based submissions. However, the measures group-specific intent G-code has been created for registry only measures groups for use by registries that utilize claims data.

  G8491: I intend to report the HIV/AIDS Measures Group

- Select patient sample method:
  **30 Patient Sample Method:** 30 unique Medicare Part B FFS (fee for service) patients meeting patient sample criteria for the measures group.
  **OR**
  **80% Patient Sample Method:** All patients meeting patient sample criteria for the measure group during the entire reporting period (January 1 through December 31, 2012 OR July 1 through December 31, 2012). For the 12-month reporting period, a minimum of 15 Medicare Part B FFS patients must meet the measures group patient sample criteria to report satisfactory. For the 6-month reporting period, a minimum of 8 Medicare Part B FFS patients must meet the measures group patient sample criteria to report satisfactory.

- Patient sample criteria for the HIV/AIDS Measures Group are patients aged 13 years and older with a specific diagnosis of HIV/AIDS accompanied by a specific patient encounter:

  **One of the following diagnosis codes indicating HIV/AIDS:** 042, 079.53, V08

  **Accompanied by**

  **One of the following patient encounter codes:** 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215

- Report a numerator option on all measures within the HIV/AIDS Measures Group for each patient within the eligible professional's patient sample.
Instructions for qualifying numerator option reporting for each of the measures within the HIV/AIDS Measures Group are displayed on the next several pages. The following composite G-code has been created for registry only measures groups for use by registries that utilize claims data. This composite G-code may be reported in lieu of the individual quality-data codes for each of the measures within the group, if all quality actions for the patient have been performed for all the measures within the group. However, it is not necessary to submit the following composite G-code for registry-based submissions.

**Composite G-code G8500:** All quality actions for the applicable measures in the HIV/AIDS Measures Group have been performed for this patient.

To report satisfactorily for the HIV/AIDS Measures Group it requires **all** measures for each patient within the eligible professional’s patient sample to be reported a minimum of once during the reporting period. Measure #159 will be reported once during the reporting period for measures group purposes.

Measures groups containing a measure with a 0% performance rate will not be counted as satisfactorily reporting the measures group. The recommended clinical quality action must be performed on at least one patient for each measure within the measures group reported by the eligible professional. Performance exclusion quality data codes are not counted in the performance denominator. If the eligible professional submits all performance exclusion quality data codes, the performance rate would be 0/0 and would be considered satisfactorily reporting.

When using the 30 Patient Sample Method, report all measures for the 30 unique Medicare Part B FFS patients seen. When using the 80% Patient Sample Method, report all measures on at least 80% of the patient sample for the eligible professional for the 12-month or 6-month reporting period.

NOTE: The detailed instructions in this specification apply exclusively to the reporting and analysis of the included measures under the measures groups option. For all other claims-based or registry-based reporting options, please see the measures’ full specifications in the document “2012 Physician Quality Reporting Measure Specifications Manual for Claims and Registry Reporting for Individual Measures” available for download from the CMS Physician Quality Reporting website.
Measure #159: HIV/AIDS: CD4+ Cell Count or CD4+ Percentage

**DESCRIPTION:**
Percentage of patients aged 6 months and older with a diagnosis of HIV/AIDS for whom a CD4+ cell count or CD4+ cell percentage was performed at least once every 6 months

**NUMERATOR:**
Patients with CD4+ cell count or CD4+ cell percentage performed at least once every 6 months

**Numerator Note:** Report this measure once during the reporting period for measures group purposes.

**Numerator Options:**
- CD4+ cell count or CD4+ cell percentage documented as performed (3500F)
- OR
- CD4+ cell count or percentage not documented as performed, reason not specified (3500F with 8P)

---

**NOTE:** The detailed instructions in this specification apply exclusively to the reporting and analysis of the included measures under the measures groups option. For all other claims-based or registry-based reporting options, please see the measures' full specifications in the document "2012 Physician Quality Reporting Measure Specifications Manual for Claims and Registry Reporting for Individual Measures" available for download from the CMS Physician Quality Reporting website.
Measure #160: HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis

DESCRIPTION:
Percentage of patients aged 6 years and older with a diagnosis of HIV/AIDS and CD4+ cell count < 200 cells/mm³ who were prescribed PCP prophylaxis within 3 months of low CD4+ cell count

NUMERATOR:
Patients who were prescribed PCP prophylaxis within 3 months of low CD4+ cell count

Definition:
Prescribed – May include prescription given to the patient for PCP prophylaxis therapy at one or more visits in the 12-month period OR patient already taking PCP prophylaxis therapy as documented in current medication list.

Numerator Options:
Pneumocystis Jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (4280F)
AND
CD4+ cell count < 200 cells/mm³ (3494F)
OR
Pneumocystis Jiroveci pneumonia prophylaxis not prescribed within 3 months of low CD4+ cell count or percentage for medical reason (4280F with 1P)
(i.e., patient’s CD4+ cell count above threshold within 3 months after CD4+ cell count below threshold, indicating that the patient’s CD4+ levels are within an acceptable range and the patient does not require PCP prophylaxis)
AND
CD4+ cell count < 200 cells/mm³ (3494F)

OR
CD4+ cell count 200 – 499 cells/mm³ (3495F)
OR
CD4+ cell count ≥ 500 cells/mm³ (3496F)
OR
CD4+ cell count not performed, reason not specified (3494F with 8P)

OR
PCP prophylaxis was not prescribed within 3 months of low CD4+ cell count, reason not specified (4280F with 8P)
AND
CD4+ cell count < 200 cells/mm³ (3494F)

NOTE: The detailed instructions in this specification apply exclusively to the reporting and analysis of the included measures under the measures groups option. For all other claims-based or registry-based reporting options, please see the measures’ full specifications in the document “2012 Physician Quality Reporting Measure Specifications Manual for Claims and Registry Reporting for Individual Measures” available for download from the CMS Physician Quality Reporting website.
## Measure #161: HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy

**DESCRIPTION:**
Percentage of patients with a diagnosis of HIV/AIDS aged 13 years and older: who have a history of a nadir CD4+ cell count below 350/mm³ or who have a history of an AIDS-defining condition, regardless of CD4+ cell count; who were prescribed potent antiretroviral therapy

**NUMERATOR:**
Patients who were prescribed potent antiretroviral therapy

**Numerator Instructions:** Nadir (lowest ever) CD4+ cell count may be the present count

**Definitions:**

**Potent Antiretroviral Therapy** – Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trials. For potent antiretroviral therapy recommendations, refer to current DHHS guidelines available for download at Aids.gov.

**AIDS-defining Condition** – Conditions included in the 1993 AIDS surveillance case definition:

- Candidiasis of bronchi, trachea, or lungs;
- Candidiasis, esophageal;
- Cervical cancer, invasive;
- Coccidioidomycosis, disseminated or extrapulmonary;
- Cryptococcosis, extrapulmonary;
- Cryptosporidiosis, chronic intestinal (greater than 1 month's duration);
- Cytomegalovirus disease (other than liver, spleen, or nodes);
- Cytomegalovirus retinitis (with loss of vision);
- Encephalopathy, HIV-related;
- Herpes simplex: chronic ulcer(s) (greater than 1 month's duration);
- Bronchitis, pneumonitis, or esophagitis;
- Histoplasmosis, disseminated or extrapulmonary;
- Isosporiasis, chronic intestinal (greater than 1 month's duration);
- Kaposi's sarcoma;
- Lymphoma, Burkitt's (or equivalent term);
- Lymphoma, immunoblastic (or equivalent term);
- Lymphoma, primary, of brain;
- Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary;
- Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary);
- Mycobacterium, other species or unidentified species, disseminated or extrapulmonary;
- Pneumocystis carinii pneumonia;
- Pneumonia, recurrent;
- Progressive multifocal leukoencephalopathy;
- Salmonella septicemia, recurrent;
Toxoplasmosis of brain;
Wasting syndrome due to HIV. (NYSDOH, 2007)

**Prescribed** – May include prescription given to the patient for potent antiretroviral therapy at one or more visits in the 12-month period OR patient already taking potent antiretroviral therapy as documented in current medication list.

**Numerator Options:**
Potent antiretroviral therapy prescribed (4276F)
AND
History of nadir CD4+ cell count < 350 cells/mm³ (3492F)
OR
History of AIDS-defining condition (3490F)
OR
No history of nadir CD4+ cell count < 350 cells/mm³ AND no history of AIDS-defining condition (3493F)
OR
Potent antiretroviral therapy **not** prescribed, reason not specified (4276F with 8P)
AND
History of nadir CD4+ cell count < 350 cells/mm³ (3492F)
OR
History of AIDS-defining condition (3490F)

*NOTE: The detailed instructions in this specification apply exclusively to the reporting and analysis of the included measures under the measures groups option. For all other claims-based or registry-based reporting options, please see the measures' full specifications in the document “2012 Physician Quality Reporting Measure Specifications Manual for Claims and Registry Reporting for Individual Measures” available for download from the CMS Physician Quality Reporting website.*
Measure #162: HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy

DESCRIPTION:
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS who are receiving potent antiretroviral therapy, who have a viral load below limits of quantification after at least 6 months of potent antiretroviral therapy or patients whose viral load is not below limits of quantification after at least 6 months of potent antiretroviral therapy and have documentation of a plan of care.

NUMERATOR:
Patients with viral load below limits of quantification or patients with viral load not below limits of quantification who have a documented plan of care.

Numerator Instructions: Viral load below limits of quantification is determined using laboratory cutoff levels for reference laboratory used by clinic or provider.

Definitions:

Potent Antiretroviral Therapy – Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trials. For potent antiretroviral therapy recommendations, refer to current DHHS guidelines available for download at Aids.gov.

Plan of Care – May include altering the therapy regimen, reaffirming to the patient the importance of high adherence to the regimen, or reassessment of viral load at a specified future date.

Numerator Options:
- HIV RNA viral load below limits of quantification (3502F) AND
  Patient receiving potent antiretroviral therapy for 6 months or longer (4270F)
  OR
  - HIV RNA viral load not below limits of quantification (3503F) AND
    HIV RNA control plan of care, documented (0575F) AND
    Patient receiving potent antiretroviral therapy for 6 months or longer (4270F)
    OR
    Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (4271F)
    OR
    Viral load not performed or documented, reason not specified (3502F with 8P) AND
    Patient receiving potent antiretroviral therapy for 6 months or longer (4270F)
    OR
Plan of care for viral load not below limits of quantification was **not** documented, reason not specified (0575F with 8P)

**AND**

HIV RNA viral load not below limits of quantification (3503F)

**AND**

Patient receiving potent antiretroviral therapy for 6 months or longer (4270F)
Measure #205: HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea

DESCRIPTION:
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom chlamydia and gonorrhea screenings were performed at least once since the diagnosis of HIV infection

NUMERATOR:
Patients with chlamydia and gonorrhea screenings performed at least once since the diagnosis of HIV infection

Numerator Options:
- Chlamydia and gonorrhea screenings documented as performed (3511F)
- Chlamydia and gonorrhea screenings not documented as performed, due to patient reason (3511F with 2P)
- Chlamydia and gonorrhea screenings not documented as performed, reason not specified (3511F with 8P)

NOTE: The detailed instructions in this specification apply exclusively to the reporting and analysis of the included measures under the measures groups option. For all other claims-based or registry-based reporting options, please see the measures' full specifications in the document “2012 Physician Quality Reporting Measure Specifications Manual for Claims and Registry Reporting for Individual Measures” available for download from the CMS Physician Quality Reporting website.
Measure #206: HIV/AIDS: Screening for High Risk Sexual Behaviors

DESCRIPTION:
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS who were screened for high risk sexual behaviors at least once within 12 months

NUMERATOR:
Patients who were screened for high risk sexual behaviors at least once within 12 months

Numerator Options:
Patient screened for high risk sexual behavior (4293F)
OR
Patient not screened for high risk sexual behaviors, reason not specified (4293F with 8P)

NOTE: The detailed instructions in this specification apply exclusively to the reporting and analysis of the included measures under the measures groups option. For all other claims-based or registry-based reporting options, please see the measures’ full specifications in the document “2012 Physician Quality Reporting Measure Specifications Manual for Claims and Registry Reporting for Individual Measures” available for download from the CMS Physician Quality Reporting website.
Measure #207: HIV/AIDS: Screening for Injection Drug Use

DESCRIPTION:
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS who were screened for injection drug use at least once within 12 months

NUMERATOR:
Patients who were screened for injection drug use at least once within 12 months

Numerator Options:
Patient screened for injection drug use (4290F)

OR

Patient not screened for injection drug use, reason not specified (4290F with 8P)
Measure #208: HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis

**DESCRIPTION:**
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS who were screened for syphilis at least once within 12 months

**NUMERATOR:**
Patients who were screened for syphilis at least once within 12 months

**Numerator Options:**
- Syphilis screening documented as performed (3512F)
- Syphilis screening not documented as performed, due to patient reason (3512F with 2P)
- Syphilis screening not documented as performed, reason not specified (3512F with 8P)